SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Darakhshan J. Haleem, 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia, Behavioural Pharmacology, 2015, 26, 45

    CrossRef

  2. 2
    Nicolas Morin, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo, Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 27

    CrossRef

  3. 3
    Hayato Tabu, Toshihiko Aso, Masao Matsuhashi, Yoshino Ueki, Ryosuke Takahashi, Hidenao Fukuyama, Hiroshi Shibasaki, Tatsuya Mima, Parkinson's disease patients showed delayed awareness of motor intention, Neuroscience Research, 2015,

    CrossRef

  4. 4
    Danhui Zhang, Tanuja Bordia, Matthew McGregor, J. Michael McIntosh, Michael W. Decker, Maryka Quik, ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease, Movement Disorders, 2014, 29, 4
  5. 5
    Mohammadreza Shariatgorji, Anna Nilsson, Richard J.A. Goodwin, Patrik Källback, Nicoletta Schintu, Xiaoqun Zhang, Alan R. Crossman, Erwan Bezard, Per Svenningsson, Per E. Andren, Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections, Neuron, 2014, 84, 4, 697

    CrossRef

  6. 6
    Sarah Coakeley, Kaylena Ehgoetz Martens, Quincy J Almeida, Management of anxiety and motor symptoms in Parkinson’s disease, Expert Review of Neurotherapeutics, 2014, 14, 8, 937

    CrossRef

  7. 7
    Andrea Kistner, Eugénie Lhommée, Paul Krack, Mechanisms of Body Weight Fluctuations in Parkinson’s Disease, Frontiers in Neurology, 2014, 5,

    CrossRef

  8. 8
    Andrea Kistner, Paul Krack, Parkinson’s Disease: No Milk Today?, Frontiers in Neurology, 2014, 5,

    CrossRef

  9. 9
    C. Luo, Q. Chen, W. Song, K. Chen, X. Guo, J. Yang, X. Huang, Q. Gong, H.-F. Shang, Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 6, 675

    CrossRef

  10. 10
    Maryka Quik, Danhui Zhang, Xiomara A. Perez, Tanuja Bordia, Role for the nicotinic cholinergic system in movement disorders; therapeutic implications, Pharmacology & Therapeutics, 2014, 144, 1, 50

    CrossRef

  11. 11
    Mary V. Burke, Christine Nocjar, Alex J. Sonneborn, Andrew C. McCreary, Elizabeth A. Pehek, Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra, Journal of Neurochemistry, 2014, 131, 4
  12. 12
    Dr. Peter van Domburg, Marion Vromen, Janine Collet, Monique Durlinger, Serge Roufs, Jos Schols, Walther Sipers, Mike Verkaaik, Frans Verhey, Agitatie en agressie bij dementie: ontwerp van een evidence-based algoritme voor medicamenteuze behandeling, Tijdschrift voor Neuropsychiatrie en Gedragsneurologie, 2013, 1, 2, 36

    CrossRef

  13. 13
    Golnasim Riahi, Marc Morissette, Pershia Samadi, Martin Parent, Thérèse Di Paolo, Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia, Biochemical Pharmacology, 2013, 86, 7, 970

    CrossRef

  14. 14
    Olle Lindvall, Developing dopaminergic cell therapy for Parkinson's disease—give up or move forward?, Movement Disorders, 2013, 28, 3
  15. 15
    Margarita Valhondo, Isabel Marco, Mar Martín-Fontecha, Henar Vázquez-Villa, José A. Ramos, Reinhard Berkels, Thomas Lauterbach, Bellinda Benhamú, María L. López-Rodríguez, New Serotonin 5-HT1AReceptor Agonists Endowed with Antinociceptive Activityin Vivo, Journal of Medicinal Chemistry, 2013, 56, 20, 7851

    CrossRef

  16. 16
    Danielli Souza Speciali, Elaine Menezes de Oliveira, Nadia Maria dos Santos, Fernando Vieira Pereira, América Cristina Fracini, Thiago Yukio Fukuda, Claudia Santos Oliveira, João Carlos Correa, Paulo Roberto Garcia Lucareli, Use of the Gait Deviation Index and spatiotemporal variables for the assessment of dual task interference paradigm, Journal of Bodywork and Movement Therapies, 2013, 17, 1, 19

    CrossRef

  17. 17
    Philippe Huot, Tom H. Johnston, Lieke Winkelmolen, Susan H. Fox, Jonathan M. Brotchie, 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA, Neurobiology of Aging, 2012, 33, 1, 194.e5

    CrossRef

  18. 18
    Javier Blesa, Sudarshan Phani, Vernice Jackson-Lewis, Serge Przedborski, Classic and New Animal Models of Parkinson's Disease, Journal of Biomedicine and Biotechnology, 2012, 2012, 1

    CrossRef

  19. 19
    Golnasim Riahi, Marc Morissette, Daniel Lévesque, Claude Rouillard, Pershia Samadi, Martin Parent, Thérèse Di Paolo, Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain, Neurochemistry International, 2012, 61, 7, 1160

    CrossRef

  20. 20
    Bénédicte Ballanger, Alice Poisson, Emmanuel Broussolle, Stéphane Thobois, Functional imaging of non-motor signs in Parkinson's disease, Journal of the Neurological Sciences, 2012, 315, 1-2, 9

    CrossRef

  21. 21
    Sylvia Navailles, Philippe De Deurwaerdère, Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  22. 22
    Philippe Huot, Tom H. Johnston, Naomi P. Visanji, Tayyeba Darr, Donna Pires, Lili-Naz Hazrati, Jonathan M. Brotchie, Susan H. Fox, Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease, Movement Disorders, 2012, 27, 6
  23. 23
    Richard L. Doty, Olfaction in Parkinson's disease and related disorders, Neurobiology of Disease, 2012, 46, 3, 527

    CrossRef

  24. 24
    Lisa Glasl, Karina Kloos, Florian Giesert, Anne Roethig, Barbara Di Benedetto, Ralf Kühn, Jingzhong Zhang, Ulrich Hafen, Julia Zerle, Andreas Hofmann, Martin Hrabé de Angelis, Konstanze F. Winklhofer, Sabine M. Hölter, Daniela M. Vogt Weisenhorn, Wolfgang Wurst, Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb, Experimental Neurology, 2012, 235, 1, 214

    CrossRef

  25. 25
    Marios Politis, Paola Piccini, Positron emission tomography imaging in neurological disorders, Journal of Neurology, 2012, 259, 9, 1769

    CrossRef

  26. 26
    Benedicte Ballanger, Helene Klinger, Julien Eche, Jérôme Lerond, Anne-Evelyne Vallet, Didier Le Bars, Leon Tremblay, Véronique Sgambato-Faure, Emmanuel Broussolle, Stéphane Thobois, Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease, Movement Disorders, 2012, 27, 1
  27. 27
    M. Politis, K. Wu, C. Loane, N. P. Quinn, D. J. Brooks, W. H. Oertel, A. Bjorklund, O. Lindvall, P. Piccini, Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts, Science Translational Medicine, 2012, 4, 128, 128ra41

    CrossRef

  28. 28
    Ann M. Hemmerle, James P. Herman, Kim B. Seroogy, Stress, depression and Parkinson's disease, Experimental Neurology, 2012, 233, 1, 79

    CrossRef

  29. 29
    Vikas Kotagal, Roger L. Albin, Martijn L. T. M. Müller, Robert A. Koeppe, Ronald D. Chervin, Kirk A. Frey, Nicolaas I. Bohnen, Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease, Annals of Neurology, 2012, 71, 4
  30. 30
    P. De Deurwaerdère, S. Navailles, What can we expect from the serotonergic side of l-DOPA?, Revue Neurologique, 2012, 168, 12, 927

    CrossRef

  31. 31
    Golnasim Riahi, Marc Morissette, Martin Parent, Thérèse Di Paolo, Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias, European Journal of Neuroscience, 2011, 33, 10
  32. 32
    Graham Pluck, Richard G. Brown, Cognitive and Affective Correlates of Temperament in Parkinson's Disease, Depression Research and Treatment, 2011, 2011, 1

    CrossRef

  33. 33
    S. Nikolaus, R. Larisch, H. Vosberg, M. Beu, H. Hautzel, A. Wirrwar, H.-W. Mueller, C. Antke, In vivo imaging neurotransmitter function, Nuklearmedizin, 2011, 50, 4, 155

    CrossRef

  34. 34
    F.-M. Zhou, C.R. Lee, Intrinsic and integrative properties of substantia nigra pars reticulata neurons, Neuroscience, 2011, 198, 69

    CrossRef

  35. 35
    Mahmoud M. Iravani, Peter Jenner, Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation, Journal of Neural Transmission, 2011, 118, 12, 1661

    CrossRef

  36. 36
    Sven Parkel, Lauri Tõntson, Ago Rinken, Millimolar Mn2+ influences agonist binding to 5-HT1A receptors by inhibiting guanosine nucleotide binding to receptor-coupled G-proteins, NeuroToxicology, 2011, 32, 1, 25

    CrossRef

  37. 37
    Philippe Huot, Susan H Fox, Nondopaminergic treatments for Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 6, 491

    CrossRef

  38. 38
    T. Wichmann, J.O. Dostrovsky, Pathological basal ganglia activity in movement disorders, Neuroscience, 2011, 198, 232

    CrossRef

  39. 39
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  40. 40
    S. Fabio Falsone, Gerd Leitinger, Anita Karner, Andreas J. Kungl, Simone Kosol, Roberto Cappai, Klaus Zangger, The neurotransmitter serotonin interrupts α-synuclein amyloid maturation, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2011, 1814, 5, 553

    CrossRef

  41. 41
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  42. 42
    C.A. Jones, L.C. Johnston, M.J. Jackson, L.A. Smith, G. van Scharrenburg, S. Rose, P.G. Jenner, A.C. McCreary, An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease, European Neuropsychopharmacology, 2010, 20, 8, 582

    CrossRef

  43. 43
    Mario Coletti Moja, Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease, Movement Disorders, 2010, 25, 9
  44. 44
    Barbara Picconi, Veronica Ghiglieri, Paolo Calabresi, L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?, Annals of Neurology, 2010, 68, 5
  45. 45
    Paolo Calabresi, Massimiliano Di Filippo, Veronica Ghiglieri, Nicola Tambasco, Barbara Picconi, Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap, The Lancet Neurology, 2010, 9, 11, 1106

    CrossRef